Skip to main content
SpringerLink
Log in
Book cover

Cytokines in Severe Sepsis and Septic Shock pp 285–293Cite as

Birkhäuser

Neutralizing antibodies and receptor constructs

  • Chapter

Part of the book series: Progress in Inflammation Research ((PIR))

Abstract

Proinflammatory cytokines, including interleukin 1 (IL-1) and tumor necrosis factor (TNF), appear to play an important role in contributing to organ system dysfunction and mortality in septic patients [1]. Clinical trials investigating the endogenously produced anti-IL-1 agent, interleukin 1 receptor antagonist (IL-1ra), yielded disappointing results [2]. Several large studies have examined anti-TNF therapies in patients with sepsis, and the results of these studies, although generally negative, still suggest that there may be benefit from anti-TNF therapies in sharply defined groups of critically ill patients with overwhelming infections [3].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abraham E (1997) Emerging therapies for sepsis and septic shock. West J Med 166: 195–200

    PubMed  CAS  Google Scholar 

  2. Opal SM, Fisher CJ, Pribble JP, Dhainaut J-F, Vincent J-L, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H et al (1997) The confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 25: 1115–1124

    Article  CAS  Google Scholar 

  3. Grau GE, Maennel DN (1997) TNF inhibition and sepsis — sounding a cautionary note. Nature Med 3: 1193–1195

    Article  PubMed  CAS  Google Scholar 

  4. Abraham E, Wunderink R, Silverman H, Perl T, Nasraway S, Levy H, Bone R, Wenzel R, Balk R, Allred R, Pennington J, Wherry J (1995) Monoclonal antibody to human tumor necrosis factor alpha (TNF MAb): Efficacy and safety in patients with the sepsis syndrome. JAMA 273: 934–941

    Article  PubMed  CAS  Google Scholar 

  5. Ashkenazi A, Marsters SA, Capon DJ, Chamow SM, Figari IS, Pennica D, Goeddel DV, Palladino MA, Smith DH (1991) Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci USA 88: 10535–10539

    Article  PubMed  CAS  Google Scholar 

  6. Van Zee KJ, Moldawer LL, Oldenburg HAS, Thompson WZ, Stackpole SA, Montegut WJ, Rogy MA, Meschter C, Gallati H, Schiller CD et al (1996) Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45–2081. J Immunol 156: 2221–2230

    PubMed  Google Scholar 

  7. Haak-Frendscho M, Marsters SA, Mordenti J, Brady S, Gillett NA, Chen SA, Ashkenazi A (1994) Inhibition of TNF by a TNF receptor immunoadhesin. J Immunol 152: 1347–1353

    PubMed  CAS  Google Scholar 

  8. Sriskandan S, Moyes D, Lemm G, Cohen J (1996) Lymphotoxin-a (TNF-a) during sep-sis. Cytokine 8: 933–937

    Article  PubMed  CAS  Google Scholar 

  9. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC et al (1987) Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330: 662–664.

    Article  PubMed  CAS  Google Scholar 

  10. Fong Y, Tracey KJ, Moldawer LL et al (1989) Antibodies to cachectin/TNF reduce interleukin-1 and interleukin-6 appearance during lethal bacteremia. J Exp Med 170: 1627–1633.

    Article  PubMed  CAS  Google Scholar 

  11. Hinshaw LB, Tekamp-Olson P, Chang AC et al (1990) Survival of primates in LD 100 septic shock following therapy with antibody to tumor necrosis factor (TNF). Circ Shock 30: 279–292.

    PubMed  CAS  Google Scholar 

  12. Hinshaw LB, Emerson TE Jr., Taylor FB Jr., Chang ACK, Duerr M, Peer GT, Flournoy DJ, White GL, Kosanake SD, Murray CK, Xu R, Passey RB, Fournel MA (1992) Lethal S. aureus shock in primates: prevention of death with anti-TNF antibody. J Trauma 33: 568–573.

    Article  PubMed  CAS  Google Scholar 

  13. Fisher CJ, Opal SM, Dhainaut J-F, Stephens S, Zimmerman JL, Nightingale P, Harris SJ, Schein RMH, Panacek EA, Vincent J-L et al (1993) Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 21: 318–327

    Article  PubMed  Google Scholar 

  14. Dhainaut J-F A, Vincent J-L, Richard C, Lejeune P, Martin C, Fierobe L, Stephens S, Ney UM, Sopwith M (1995) CDPS71, a humanized antibody to human tumor necrosis factor-a: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock Crit Care Med 23: 1461–1469

    CAS  Google Scholar 

  15. Cohen J, Carlet J, for the INTERSEPT Study Group (1996) INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-a in patients with sepsis. Crit Care Med 24: 1431–1440

    Article  PubMed  CAS  Google Scholar 

  16. Abraham E, and the NORASEPT II Study Group (1997) Effect of murine monoclonal antibodies to human tumor necrosis factor (BAY x 1351) in patients with septic shock. Chest 112: 47S

    Article  Google Scholar 

  17. Reinhart K, Wiegand-Lohnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D et al (1996) Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 24: 733–742

    Article  PubMed  CAS  Google Scholar 

  18. Evans TJ, Moyes D, Carpenter A, Martin R, Loetscher H, Lesslauer W, Cohen J (1994) Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptorimmunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 180: 2173–2179

    Article  PubMed  CAS  Google Scholar 

  19. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R (1995) Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 155: 5038–5045

    PubMed  CAS  Google Scholar 

  20. Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RMH, Benjamin E, and the Soluble TNF Receptor Sepsis Study Group (1996) Treatment of patients with septic shock with tumor necrosis factor receptor Fc fusion protein. N Engl J Med 334: 1697–1702

    Article  PubMed  CAS  Google Scholar 

  21. Abraham E, Glauser MP, Butler T, Lew D, Gelmont D, Laterre PF, Kudsk K, Bruining HA, Otto C, Tobin E, Zwingelstein C, Lesslauer W, Leighton A (1997) p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: A placebo controlled, randomized, double-blind, multi-center clinical trial. JAMA 277: 1531–1538

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Box C272, 4200 E. Ninth Avenue, Denver, CO, 80262, USA

    Edward Abraham

Authors
  1. Edward Abraham
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Donaueschingenstrasse 13, A-1200, Vienna, Austria

    Heinz Redl  & Günther Schlag  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Basel AG

About this chapter

Cite this chapter

Abraham, E. (1999). Neutralizing antibodies and receptor constructs. In: Redl, H., Schlag, G. (eds) Cytokines in Severe Sepsis and Septic Shock. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8755-7_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8755-7_16

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9759-4

  • Online ISBN: 978-3-0348-8755-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation